The ARRDC3 Knockout HK-2 Cell Line is a CRISPR/Cas9-edited knockout line for targeted disruption of the ARRDC3 gene in human proximal tubule epithelial cells. This loss-of-function model enables robust investigation of ARRDC3-dependent processes in a physiologically relevant epithelial context, free from variable expression. The engineered cells provide a stable system for analyzing signaling and trafficking events.
HK-2 cells are an immortalized human proximal tubule epithelial line derived from normal adult kidney, retaining key functional properties such as solute reabsorption and secretion. Widely used for nephrotoxicity and transporter studies, they serve as an ideal background for examining renal epithelial signaling and disease mechanisms.
ARRDC3 is a multifunctional adaptor protein that bridges GPCRs and NEDD4 family ubiquitin ligases, particularly NEDD4L, to promote receptor ubiquitination and clathrin-mediated endocytosis. It interacts with ??-arrestins, the AP-2 complex, and clathrin to facilitate internalization of receptors such as the beta-2 adrenergic receptor (??2-AR). ARRDC3 also modulates NF-??B activation and JNK phosphorylation, partly through Src kinase. Upstream regulators include hypoxia-activated HIF-1??, inflammatory cytokines like TNF-??, and GPCR ligands such as isoproterenol and angiotensin II. Knockout of ARRDC3 therefore disrupts coordinated receptor trafficking and downstream signaling, causing aberrant ubiquitin-dependent degradation and altered NF-??B and JNK pathway activity.
In HK-2 proximal tubule cells, ARRDC3 knockout provides a powerful tool to dissect the interplay between GPCR signaling, ubiquitination, and epithelial stress responses. These cells are exposed to diverse GPCR ligands and are vulnerable to hypoxic and inflammatory insults that engage ARRDC3. Deleting ARRDC3 enables investigation of how receptor trafficking and stability, NF-??B and JNK activation, and cellular responses to nephrotoxic agents are altered. This model is particularly valuable for studying mechanisms of kidney injury, metabolic disorders, and the potential tumor-suppressive roles of ARRDC3 in renal cancers.
Applications include GPCR endocytosis and ubiquitination studies using ??2-AR internalization assays, ubiquitin-specific Western blotting, and co-immunoprecipitation with NEDD4L. NF-??B and JNK signaling analyses via luciferase reporters and phospho-JNK detection are straightforward, and immunofluorescence can visualize changes in clathrin-coated pits. The line also supports drug toxicity screening and pharmacodynamics studies in a renal epithelial background. For further details, contact Ascent Research.
